Designing a post-genomics knowledge ecosystem to translate pharmacogenomics into public health action

Genome Medicine

Volumn 4, Issue 11, 2012, Pages

  Dove, Edward S ^a,c   Faraj, Samer A ^b   Kolker, Eugene ^d,e,f   Özdemir, Vural ^b,c,f  

^a Columbia Law School LLM Program ^*  (United States)

^b MCGILL UNIVERSITY   (Canada)

^c MCGILL UNIVERSITY   (Canada)

^d SEATTLE CHILDREN S HOSPITAL   (United States)

^e UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^f Data Enabled Life Sciences Alliance International DELSA Global   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CITIZENSHIP; CONSULTATION; DRUG METABOLISM; GENETIC SCREENING; HUMAN; HUMAN GENOME PROJECT; KNOWLEDGE BASE; NANOTECHNOLOGY; PATENT; PATIENT ADVOCACY; PHARMACOGENETICS; PHARMACOGENOMICS; POLITICS; PRIORITY JOURNAL; PUBLIC HEALTH; PUBLIC HEALTH SERVICE; SOCIAL MEDICINE; SOCIETY; SPECIALIZATION; TRANSLATIONAL RESEARCH;

EID: 84869870038     PISSN: None     EISSN: 1756994X     Source Type: Journal    
DOI: 10.1186/gm392     Document Type: Article

References (62)

1. Choi BC, Pang T, Lin V, Puska P, Sherman G, Goddard M, Ackland MJ, Sainsbury P, Stachenko S, Morrison H, Clottey C. Can scientists and policy makers work together?. J Epidemiol Community Health 2005, 59:632-637. 10.1136/jech.2004.031765, 1733111, 16020638.
2. Tutu D, Tutu M. Made for Goodness: And Why This Makes All the Difference 2010, New York: HarperCollins Publishers.
3. Özdemir V, Husereau D, Hyland S, Samper S, Salleh MZ. Personalized medicine beyond genomics: new technologies, global health diplomacy and anticipatory governance. Curr Pharmacogenomics Person Med 2009, 7:225-230. 2886025, 20613883.
4. Veblen T. The Instinct of Workmanship and the State of the Industrial Arts 1914, New York: Macmillan.
5. Oliver S, Gray J. A Bibliography of Research Reports about Patients', Clinicians' and Researchers'' Priorities for New Research 2006, London: James Lind Alliance, 3314621, 22470554.
6. Chalmers I, Glasziou P. Avoidable waste in the production and reporting of research evidence. Lancet 2009, 374:86-89. 10.1016/S0140-6736(09)60329-9, 19525005.
7. Society for Social Studies of Science. , http://www.4sonline.org/
8. Bourdieu P. Outline of a Theory of Practice 1977, Cambridge: Cambridge University Press.
9. Bourdieu P, Wacquant L. An Invitation to Reflexive Sociology 1992, Chicago: University of Chicago Press.
10. Rindova V, Yeow A, Martin L, Faraj S. Partnering portfolios, value-creation logics, and growth trajectories: a comparison of Yahoo and Google (1995-2007). Strategic Entrepreneurship J 2012, 6:133-151.
11. Majchrzak A, More P, Faraj S. Transcending knowledge differences in cross-functional teams. Organization Sci 2012, 23:951-970.
12. Holmes BJ. A broader perspective on personalized medicine: lessons from discourse analysis and knowledge translation. Curr Pharmacogenomics Person Med 2012, 10:179-181.
13. Faraj S, Kolker E, Bevilacqua L, Özdemir V. Collective theranostics and postgenomics entrepreneurship: Rethinking innovations as knowledge ecosystems built by complex collaboration. Expert Rev Mol Diagn
14. Dove ES. The genetic privacy carousel: A discourse on proposed genetic privacy bills and the co-evolution of law and science. Curr Pharmacogenomics Person Med 2011, 9:252-263.
15. Özdemir V, Cho WCS. Theranostics: Rethinking post-genomics diagnostics. Expert Rev Mol Diagn
16. Dandara C, Adebamowo C, de Vries J, Dove ES, Fisher E, Gibbs RA, Hotez PJ, Kickbusch I, Knoppers BM, Masellis M, Oestergaard MZ, Pang T, Rotimi CN. An idea whose time has come? An African foresight observatory on genomics medicine and data-intensive global science. Curr Pharmacogenomics Person Med 2012, 10:7-15.
17. Pang T. Pharmacogenomics and personalized medicine for the developing world - too soon or just-in-time? A personal view from the World Health Organization. Curr Pharmacogenomics Person Med 2009, 7:149-157.
18. Ravetz J. 'Climategate' and the maturing of post-normal science. Futures 2011, 43:149-157.
19. Kickbusch I. Tackling the political determinants of global health. BMJ 2005, 331:246-247. 10.1136/bmj.331.7511.246, 1181253, 16051991.
20. European Commission EUR 22700 - Science & Governance - Taking European Knowledge Society Seriously 2007, Luxembourg: Office for Official Publications of the European Communities, European Commission.
21. Guston DH, Sarewitz D, Miller C. Scientists not immune to partisanship. Science 2009, 323:582.
22. Özdemir V, Fisher E, Dove ES, Burton H, Wright GE, Masellis M, Warnich L. End of the beginning and public health pharmacogenomics: knowledge in 'mode 2' and P5 medicine. Curr Pharmacogenomics Person Med 2012, 10:1-6. 10.2174/1875692111201010001, 3338471, 22545073.
23. Dove ES, Özdemir V. 'Regular science' is inherently political. EMBO Rep
24. Gibbons M, Limoges C, Nowotny H. The New Production of Knowledge 1994, London: Sage.
25. Nowotny H, Scott P, Gibbons M. Re-Thinking Science: Knowledge and the Public in an Age of Uncertainty 2001, Cambridge: Polity Press.
26. Nowotny H, Scott P, Gibbons M. 'Mode 2' revisited: The new production of knowledge. Minerva 2003, 41:179-194.
27. Gibbons M. 1997 Beanland Lecture. What Kind of University? Research and Teaching in the 21st Century 1997, Melbourne: Victoria University of Technology.
28. Khatib F, Cooper S, Tyka MD, Xu K, Makedon I, Popovic Z, Baker D, Players F. Algorithm discovery by protein folding game players. Proc Natl Acad Sci USA 2011, 108:18949-18953. 10.1073/pnas.1115898108, 3223433, 22065763.
29. The Royal Society Science as an Open Enterprise, London 2012, The Royal Society.
30. Prainsack B. Book review: Elias G. Carayannis and David F.J. Campbell, Mode 3 Knowledge Production in Quadruple Helix Innovation Systems: 21st-Century Democracy, Innovation, and Entrepreneurship for Development. Minerva 2012, 50:139-142.
31. Özdemir V, Faraj SA, Knoppers BM. Steering vaccinomics innovations with anticipatory governance and participatory foresight. OMICS 2011, 15:637-646. 10.1089/omi.2011.0087, 21848419.
32. Wynne B. Daring to imagine , http://www.india-seminar.com/2009/597/597_brian_wynne.htm
33. Özdemir V, Knoppers BM. From government to anticipatory governance. Responding to challenges set by emerging technologies and innovation. Governance for Health in the 21st Century New York: Springer, Kickbusch I, .
34. Rose N, Novas C. Biological citizenship. Global Assemblages: Technology, Politics, and Ethics as Anthropological Problems 2005, 439-463. Oxford: Blackwell, Ong A, Collier S.
35. Tutton R, Prainsack B. Enterprising or altruistic selves? Making up research subjects in genetics research. Sociol Health Illn 2011, 33:1081-1095. 10.1111/j.1467-9566.2011.01348.x, 21507012.
36. Khoury MJ, Gwinn M, Yoon PW, Dowling N, Moore CA, Bradley L. The continuum of translation research in genomic medicine: how can we accelerate the appropriate integration of human genome discoveries into health care and disease prevention?. Genet Med 2007, 9:665-674. 10.1097/GIM.0b013e31815699d0, 18073579.
37. Collins FS. Reengineering translational science: the time is right. Sci Transl Med 2011, 3:90cm17. 10.1126/scitranslmed.3002747, 21734173.
38. Ostrom E. Collective action and the evolution of social norms. J Econ Persp 2000, 14:137-158.
39. Hedgecoe A. Bioethics and the reinforcement of socio-technical expectations. Soc Stud Sci 2010, 40:163-186. 10.1177/0306312709349781, 20527320.
40. Schicktanz S, Schweda M, Wynne B. The ethics of 'public understanding of ethics' - why and how bioethics expertise should include public and patients' voices. Med Health Care Philos 2012, 15:129-139. 10.1007/s11019-011-9321-4, 3319876, 21448745.
41. Özdemir V, Joly Y, Kirby E, Avard D, Knoppers BM. Beyond ELSIs - where to from here? From 'regulating' to anticipating and shaping the innovation trajectory in personalized medicine. Pharmacogenomics: Challenges and Opportunities in Therapeutic Implementation Amsterdam: Elsevier, Lam YWF, Cavallari L, .
42. Marris C, Rose N. Open engagement: exploring public participation in the biosciences. PLoS Biol 2010, 8:e1000549. 10.1371/journal.pbio.1000549, 2994659, 21151343.
43. Stirling A. Opening up the politics of knowledge and power in bioscience. PLoS Biol 2012, 10:e1001233. 10.1371/journal.pbio.1001233, 3250508, 22235193.
44. Dijkstra AM, Gutteling JM, Swart JAA, Wieringa NF, van der Windt HJ, Seydel ER. Public participation in genomics research in the Netherlands: validating a measurement scale. Public Understand Sci 2012, 21:465-477.
45. Lehoux P, Daudelin G, Abelson J. The unbearable lightness of citizens within public deliberation processes. Soc Sci Med 2012, 74:1843-1850. 10.1016/j.socscimed.2012.02.023, 22464908.
46. Arnstein S. A ladder of citizen participation. J Am Inst Plann 1969, 35:216-224.
47. New York Times Staff The 7th annual year in ideas. NY Times (Print) 2007, 80. New York Times Staff., http://www.nytimes.com
48. Wilsdon J, Wills R. See-through Science: Why Public Engagement Needs to Move Upstream 2004, London: Demos.
49. Rowe G, Frewer LJ. A typology of public engagement mechanisms. Sci Technol Human Values 2005, 30:251-290.
50. van der Merwe R, Meehan A. Direct deliberative governance online: consensual problem solving or accommodated pluralism?. J Information Technol Politics 2012, 9:46-63.
51. Abbot C. Bridging the gap - non-state actors and the challenges of regulating new technology. J Law Soc 2012, 39:329-358.
52. Kurian P, Wright J. Science, governance, and public participation: An analysis of decision making on genetic modification in Aotearoa/New Zealand. Public Understand Sci 2012, 21:447-464.
53. Dove ES, Joly Y, Knoppers BM. Power to the people: a wiki-governance model for biobanks. Genome Biol 2012, 13:158. 10.1186/gb-2012-13-5-158, 22647613.
54. Noveck BS. Wiki Government: How Technology Can Make Government Better, Democracy Stronger, and Citizens More Powerful 2009, Washington, DC: Brookings Institution Press.
55. Laurie G. Reflexive governance in biobanking: on the value of policy led approaches and the need to recognise the limits of law. Hum Genet 2011, 130:347-356. 10.1007/s00439-011-1066-x, 21766192.
56. O'Doherty KC, Burgess MM, Edwards K, Gallagher RP, Hawkins AK, Kaye J, McCaffrey V, Winickoff DE. From consent to institutions: designing adaptive governance for genomic biobanks. Soc Sci Med 2011, 73:367-374. 10.1016/j.socscimed.2011.05.046, 21726926.
57. Papaioannou T. From consultation to deliberation? A qualitative case study of governing science and technology projects for the public good. Crit Public Health 2012, 22:235-251.
58. Knoppers BM. Genomics and policymaking: from static models to complex systems?. Hum Genet 2009, (125:):375-379.
59. Chalise P, Batzler A, Abo R, Wang L, Fridley BL. Simultaneous analysis of multiple data types in pharmacogenomic studies using weighted sparse canonical correlation analysis. OMICS 2012, 16:363-373. 10.1089/omi.2011.0126, 22734853.
60. Shanker A. Genome research in the cloud. OMICS 2012, 16:422-428. 10.1089/omi.2012.0001, 22734722.
61. Veenstra DL, Piper M, Haddow JE, Pauker SG, Klein R, Richards CS, Tunis SR, Djulbegovic B, Marrone M, Lin JS, Berg AO, Calonge N. Improving the efficiency and relevance of evidence-based recommendations in the era of whole-genome sequencing: an EGAPP methods update. Genet Med
62. Bauman Z. Liquid Modernity 2000, Cambridge, UK: Polity Press.